Table 2.
The correlations between IDO1, IDO2, TDO, and Ki67 expression and survival of glioma patients.
| Variable | Total number of patient events | Death | Survival (month) | |||
|---|---|---|---|---|---|---|
| Number | % | Mean | 95% CI | P | ||
| IDO1+ | 13 | 6 | 46.15 | 13.18 | 9.60–16.76 | 0.025 |
| IDO1− | 30 | 5 | 16.67 | 19.46 | 16.78–22.15 | |
| IDO2+ | 12 | 4 | 33.33 | 12.94 | 9.11–16.78 | 0.187 |
| IDO2− | 31 | 7 | 22.58 | 18.88 | 16.34–21.41 | |
| TDO+ | 23 | 7 | 30.43 | 12.95 | 10.44–15.46 | 0.047 |
| TDO− | 20 | 4 | 20.00 | 20.00 | 17.53–22.47 | |
| IDO1+TDO+ | 9 | 4 | 44.44 | 11.60 | 7.56–15.74 | 0.018 |
| IDO1–TDO− | 16 | 2 | 12.50 | 20.75 | 18.07–23.44 | |
| Ki67 high (≥mean) | 23 | 8 | 34.78 | 14.44 | 15.65–20.18 | 0.047 |
| Ki67 low (<mean) | 17 | 3 | 17.65 | 17.92 | 11.13–17.76 | |